Rendering

Component: (Network and Table)
Network
127 - Disclosure - Summary of Significant Accounting Policies and Estimates (Tables)
(http://www.eksobionics.com/role/SummaryOfSignificantAccountingPoliciesAndEstimatesTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Accounting Policies [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
Accounting Policies [Abstract]
 
Schedule of Accumulated Other Comprehensive Income (Loss)
The change in accumulated other comprehensive income (loss) presented on the consolidated balance sheets for the year ended December 31, 2016, is reflected in the table below net of tax:
 
 
 
Foreign
 
 
 
Currency
 
 
 
Translation
 
Balance at December 31, 2015
 
$
(1)
 
Other comprehensive loss before reclassification
 
 
80
 
Amounts reclassified from accumulated other comprehensive income (loss)
 
 
-
 
Net current period other comprehensive income
 
 
80
 
Balance at December 31, 2016
 
$
79
 
 
 
Schedule of Customer Deposits, Advances, Deferred Revenues, and Deferred Unit Costs
Deferred revenues and deferred cost of revenues consisted of the following:
 
 
 
December 31,
 
 
 
2016
 
2015
 
Customer deposits and advances
 
$
47
 
$
48
 
Deferred medical device revenues
 
 
-
 
 
7,388
 
Deferred rental income
 
 
60
 
 
71
 
Deferred extended maintenance and support
 
 
1,523
 
 
1,066
 
Total deferred revenues
 
 
1,630
 
 
8,573
 
Less current portion
 
 
(825)
 
 
(3,960)
 
Deferred revenues, non-current
 
$
805
 
$
4,613
 
 
 
 
 
 
 
 
 
Deferred medical device unit costs
 
$
-
 
$
4,590
 
Less current portion
 
 
-
 
 
(2,088)
 
Deferred cost of revenue, non-current
 
$
-
 
$
2,502
 
 
 
Schedule of basic and diluted net income (loss) per share
Basic net loss per share of common stock is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted average number of common stock, adjusted to include conversion of certain stock options and warrants for common stock during the period, as follows:
 
 
 
Years ended December 31,
 
 
 
2016(1)
 
 
2015
 
 
2014
 
Numerator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss applicable to common stockholders
 
$
(33,815)
 
 
$
(24,245)
 
 
$
(33,769)
 
Adjustment for gain on fair value of warrant liability
 
 
(4,286)
 
 
 
(2,505)
 
 
 
-
 
Adjusted net loss used for dilution calculation
 
$
(38,101)
 
 
$
(26,750)
 
 
$
(33,769)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Denominator
 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average number of shares outstanding
 
 
18,126
 
 
 
14,606
 
 
 
11,181
 
Effect of potential dilutive shares
 
 
496
 
 
 
3
 
 
 
-
 
Dilutive weighted-average number of shares outstanding
 
 
18,622
 
 
 
14,609
 
 
 
11,181
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss per share applicable to common stockholders
 
 
 
 
 
 
 
 
 
 
 
 
Basic
 
$
(1.87)
 
 
$
(1.66)
 
 
$
(3.02)
 
Diluted
 
$
(2.05)
 
 
$
(1.83)
 
 
$
(3.02)
 
(1)
Recognition of previously deferred revenue and cost of goods in the year ended December 31, 2016 reduced net loss applicable to common stockholders by $2,358, or $0.13 per share (see Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition).
 
 
Schedule of Antidilutive Securities
The following potential dilutive securities were excluded from the computation of diluted net loss per share because including them would have been anti-dilutive:
 
 
 
Years ended December 31,
 
 
 
2016
 
 
2015
 
 
2014
 
Options to purchase common stock
 
 
2,477
 
 
 
1,963
 
 
 
1,542
 
Warrants for common stock
 
 
1,963
 
 
 
1,963
 
 
 
1,971
 
Common stock issuable upon conversion of preferred shares
 
 
-
 
 
 
1,876
 
 
 
-
 
Total common stock equivalents
 
 
4,440
 
 
 
5,802
 
 
 
3,513